BRCA1 and hypoparathyroidism-retardation-dysmorphism syndrome: Homologous recombination deficiency (HRD) associated with the BRCA1/2 pathogenic variants is present only in 30% of the ovarian cancer tumors, meaning the remaining 70% are attributable to other genes.5